Clinical Trial

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Protocol Amendment History 3 changes
notable Trial sites expanded: 22 -> 25 locations 2026-06-05
notable Trial sites expanded: 11 -> 15 locations 2026-04-18
notable Trial sites expanded: 5 -> 9 locations 2026-04-03
Trial Details
NCT Number NCT07197866
Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC
Conditions Multiple System Atrophy
Enrollment 200 participants
Start Date 2025-09-30
Primary Completion 2029-05-03 (estimated)
Study Completion 2029-05-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-07